What To Know Before Buying Stock?: Akebia Therapeutics, Inc., (NASDAQ: AKBA)

 

On Monday, November 16, 2020, the Company, Akebia Therapeutics, Inc., AKBA stock construct a change of 2.36 percent (Gain) in a total of its share price and having its trading value $2.6, which belongs to Healthcare sector and Biotechnology industry. The company?s Market capitalization was $365.43M with the total Outstanding Shares of 143.32M.

 


P/S, P/E, P/B & P/C values of (NASDAQ: AKBA):

 

Akebia Therapeutics, Inc. institutional ownership is standing at 75.7 percent, while insider ownership is 0.3 percent. As of now, AKBA has a P/S, P/E and, P/B values of 1.19, 0, and 1.17 respectively. Its P/Cash is valued at 1.36.

 

The stock SMA50 is now at -6.04 percent. In looking, the SMA 200 we see that the stock has seen a -68.13 percent. The Company?s net profit margin for the 12 months at 0 percent. Comparatively, the gazes have a Gross margin of 59.3 percent.


Profitability ratios:

 

Looking into the profitability ratios of AKBA stock, an investor will find its ROE, ROA, ROI standing at -105.7 percent, -52.5 percent and, -59.4 percent, respectively.


Beta Factor:

 

A beta factor is used to measure the volatility of the stock. The stock remaining at 6.15 percent volatile for the week and 10.69 percent for the month.


Gross / Operating Margins of AKBA:

 

It calculates how much out of every dollar of sales a company actually keeps in earnings. Gross Margin is seen at 59.3 percent & Operating Margin seen at 0 percent.


Target Price:

 

Target Price informs the investors, aÿstockÿsurvey at which a trader is willing to buy or sell aÿstock.ÿAt which a trader projects that a buyer will buy a product. The company Akebia Therapeutics, Inc. recorded it at $0.


Historical Performance In The News:

 

Taking a look at the performance of Akebia Therapeutics, Inc. stock, an investor will come to know that the weekly performance for this stock is valuing at 6.12 percent, resulting in a performance for the month at -31.22 percent.

Therefore, the stated figure displays a quarterly performance of -75.56 percent, bringing six-month performance to -78.13 percent and year to date performance of -58.86 percent. As of now, Akebia Therapeutics, Inc. has a P/S, P/E and, P/B values of 1.19, 0, and 1.17 respectively. Its P/Cash is valued at 1.36.


Earnings per Share Details of Akebia Therapeutics, Inc.:

 

The EPS of AKBA is strolling at -2.97, measuring its EPS growth this year at 4.5 percent. As a result, the company has an EPS growth of 61.3 percent for the approaching year.